Commonwealth Equity Services’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Commonwealth Equity Services’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-4,024	Closed	-$431	–	3966
2023 Q1	$431	Sell	4,024 -285	-7%	-$32.8K	﹤0.01%	2679
2022 Q4	$473K	Sell	4,309 -3	-0.1%	-$195	﹤0.01%	2515
2022 Q3	$254K	Buy	+4,312	New	+$197K	﹤0.01%	2958

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Commonwealth Equity Services's RXDX Position: Q2 2023 in Review

Commonwealth Equity Services sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 4,024 shares — an estimated $431 sold.

Commonwealth Equity Services first reported a position in RXDX in Q3 2022 and held it in 3 quarters. The position peaked at $473K in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Commonwealth Equity Services reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Commonwealth Equity Services sold 4,024 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $431.
Commonwealth Equity Services first reported a position in Prometheus Biosciences, Inc. Common Stock in Q3 2022 and held it in 3 quarters.
Commonwealth Equity Services's Prometheus Biosciences, Inc. Common Stock position peaked at $473K in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Commonwealth Equity Services's 13F filing for Q2 2023, filed 10 Aug 2023.